Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

High temporal resolution 3D gadolinium-enhanced dynamic MR imaging of renal tumors with pharmacokinetic modeling: preliminary observations.

Chandarana H, Amarosa A, Huang WC, Kang SK, Taneja S, Melamed J, Kim S.

J Magn Reson Imaging. 2013 Oct;38(4):802-8. doi: 10.1002/jmri.24035. Epub 2013 Feb 6.

PMID:
23389833
2.

Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma.

Young JR, Coy H, Kim HJ, Douek M, Lo P, Pantuck AJ, Raman SS.

AJR Am J Roentgenol. 2017 Apr;208(4):812-819. doi: 10.2214/AJR.16.17152. Epub 2017 Jan 26.

PMID:
28125273
3.

Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings.

Sun MR, Ngo L, Genega EM, Atkins MB, Finn ME, Rofsky NM, Pedrosa I.

Radiology. 2009 Mar;250(3):793-802. doi: 10.1148/radiol.2503080995.

PMID:
19244046
4.
5.

Discrimination of benign and malignant breast lesions by using shutter-speed dynamic contrast-enhanced MR imaging.

Huang W, Tudorica LA, Li X, Thakur SB, Chen Y, Morris EA, Tagge IJ, Korenblit ME, Rooney WD, Koutcher JA, Springer CS Jr.

Radiology. 2011 Nov;261(2):394-403. doi: 10.1148/radiol.11102413. Epub 2011 Aug 9.

6.

Reproducibility of Dynamic Contrast-Enhanced MRI in Renal Cell Carcinoma: A Prospective Analysis on Intra- and Interobserver and Scan-Rescan Performance of Pharmacokinetic Parameters.

Wang H, Su Z, Ye H, Xu X, Sun Z, Li L, Duan F, Song Y, Lambrou T, Ma L.

Medicine (Baltimore). 2015 Sep;94(37):e1529. doi: 10.1097/MD.0000000000001529.

7.

Solid pancreatic lesions: characterization by using timing bolus dynamic contrast-enhanced MR imaging assessment--a preliminary study.

Kim JH, Lee JM, Park JH, Kim SC, Joo I, Han JK, Choi BI.

Radiology. 2013 Jan;266(1):185-96. doi: 10.1148/radiol.12120111. Epub 2012 Nov 28.

PMID:
23192779
8.

Dynamic contrast-enhanced magnetic resonance imaging assessment of kidney function and renal masses: single slice versus whole organ/tumor.

Winter KS, Helck AD, Ingrisch M, Staehler M, Stief C, Sommer WH, Braunagel M, Kazmierczak PM, Reiser MF, Nikolaou K, Notohamiprodjo M.

Invest Radiol. 2014 Nov;49(11):720-7. doi: 10.1097/RLI.0000000000000075.

PMID:
24901546
9.

Diffusion-weighted intravoxel incoherent motion imaging of renal tumors with histopathologic correlation.

Chandarana H, Kang SK, Wong S, Rusinek H, Zhang JL, Arizono S, Huang WC, Melamed J, Babb JS, Suan EF, Lee VS, Sigmund EE.

Invest Radiol. 2012 Dec;47(12):688-96. doi: 10.1097/RLI.0b013e31826a0a49.

PMID:
22996315
10.

MRI features of renal oncocytoma and chromophobe renal cell carcinoma.

Rosenkrantz AB, Hindman N, Fitzgerald EF, Niver BE, Melamed J, Babb JS.

AJR Am J Roentgenol. 2010 Dec;195(6):W421-7. doi: 10.2214/AJR.10.4718.

PMID:
21098174
11.

MR imaging in the evaluation of small (< or =3.0 cm) renal masses.

Rofsky NM, Bosniak MA.

Magn Reson Imaging Clin N Am. 1997 Feb;5(1):67-81. Review.

PMID:
8995125
12.

Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings.

Lanzman RS, Robson PM, Sun MR, Patel AD, Mentore K, Wagner AA, Genega EM, Rofsky NM, Alsop DC, Pedrosa I.

Radiology. 2012 Dec;265(3):799-808. doi: 10.1148/radiol.12112260. Epub 2012 Oct 9.

13.

Transcytolemmal water exchange in pharmacokinetic analysis of dynamic contrast-enhanced MRI data in squamous cell carcinoma of the head and neck.

Kim S, Quon H, Loevner LA, Rosen MA, Dougherty L, Kilger AM, Glickson JD, Poptani H.

J Magn Reson Imaging. 2007 Dec;26(6):1607-17.

PMID:
17968962
14.

Uncertainty in MR tracer kinetic parameters and water exchange rates estimated from T1-weighted dynamic contrast enhanced MRI.

Zhang J, Kim S.

Magn Reson Med. 2014 Aug;72(2):534-45. doi: 10.1002/mrm.24927. Epub 2013 Sep 4.

15.

Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes.

Vargas HA, Chaim J, Lefkowitz RA, Lakhman Y, Zheng J, Moskowitz CS, Sohn MJ, Schwartz LH, Russo P, Akin O.

Radiology. 2012 Sep;264(3):779-88. doi: 10.1148/radiol.12110746. Epub 2012 Jul 24.

PMID:
22829683
16.

Routinely performed multiparametric magnetic resonance imaging helps to differentiate common subtypes of renal tumours.

Cornelis F, Tricaud E, Lasserre AS, Petitpierre F, Bernhard JC, Le Bras Y, Yacoub M, Bouzgarrou M, Ravaud A, Grenier N.

Eur Radiol. 2014 May;24(5):1068-80. doi: 10.1007/s00330-014-3107-z. Epub 2014 Feb 21.

PMID:
24557052
17.

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM.

J Clin Oncol. 2008 Oct 1;26(28):4572-8. doi: 10.1200/JCO.2007.15.5655.

18.

Optimizing MRI scan time in the computation of pharmacokinetic parameters (K(trans) ) in breast cancer diagnosis.

Jena A, Mehta SB, Taneja S.

J Magn Reson Imaging. 2013 Sep;38(3):573-9. doi: 10.1002/jmri.24008. Epub 2013 Jan 24.

PMID:
23349046
19.

Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes.

Kauffman EC, Barocas DA, Chen YT, Yang XJ, Scherr DS, Tu JJ.

J Urol. 2009 May;181(5):2305-11. doi: 10.1016/j.juro.2009.01.003. Epub 2009 Mar 19.

PMID:
19303095
20.

Oncocytic renal neoplasms: diagnostic considerations.

Abrahams NA, Tamboli P.

Clin Lab Med. 2005 Jun;25(2):317-39, vi. Review.

PMID:
15848739

Supplemental Content

Support Center